Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery

Neurosurgery

Volumn 45, Issue 4, 1999, Pages 780-785

  Karinen, Petri ^a,b   Koivukangas, Pirjo ^a   Ohinmaa, Arto ^b   Koivukangas, John ^c   Öhman, Juha ^b  

^a Department of Neurosurgery ^*  (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cost effectiveness; Life expectancy; Life years gained; Nimodipine; Subarachnoid hemorrhage

Indexed keywords

NIMODIPINE;

ADOLESCENT; ADULT; AGED; ANEURYSM SURGERY; ARTICLE; BRAIN ARTERY ANEURYSM RUPTURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HOSPITAL CHARGE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

EID: 0032857955     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199910000-00009     Document Type: Article

References (28)

1. Barker FG II, Ogilvy CS: Efficacy of prophylactic nimodipine for delayed ischémie deficit after subarachnoid hemorrhage: A metaanalysis. J Neurosurg 84:405-414, 1996.
2. Canadian Coordinating Office for Health Technology Assessment: A Guidance Document for the Costing Process, version 1.0. Ottawa, Ontario, Canadian Coordinating Office for Health Technology Assessment, 1996.
3. Drummond M, Stoddart G, Torrance G: Methods for the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press, 1987.
4. Fridriksson SM, Hillman J, Säveland H, Brandt L: Intracranial aneurysm surgery in the 8th and 9th decades of life: Impact on population-based management outcome. Neurosurgery 37:627-632, 1995.
5. Goldman L, Weinstein MC, Goldman PA, Williams LW: Costeffectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265:1145-1151, 1991.
6. Hay JW, Wittels EH, Gotto AM: An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 67:789-796, 1991.
7. Hemesniemi J, Vapalahti M, Niskanen M, Tapaninaho A, Kari A, Luukkonen M, Puranen M, Saari T, Rajpar M: One-year outcome in early aneurysm surgery: A14 years experience. Acta Neurochir (Wien) 122:1-10, 1993.
8. Holloway RG, Witter DM Jr, Lawton KB, Lipscomp J, Samsa G: Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 46:854-860, 1996.
9. Johannesson M, Borgquist L, Jönsson B, Lindholm LH: The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med 240:23-29, 1996.
10. King JT Jr, Click HA, Mason TJ, Flamm ES: Elective surgery for asymptomatic, unruptured, intracranial aneurysms: A costeffectiveness analysis. J Neurosurg 83:403-412, 1995.
11. Langley PC: Therapy evaluation, patient distribution, and costoutcomes ratios. Clin Ther 17:341-347, 1995.
12. Ng YK: Welfare Economics. London, MacMillan Press, 1992.
13. ohman J, Heiskanen O: Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 69:683-686, 1988.
14. Öhman J, Servo A, Heiskanen O: Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 74:8-13, 1991.
15. Pickard JD, Bailey S, Sanderson H, Rees M, Garfield JS: Steps towards cost-benefit analysis of regional neurosurgical care. BMJ 301:629-635, 1990.
16. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P, Sinar J, Bailey S, Skene A: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British Aneurysm Nimodipine Trial. BMJ 298:636-642, 1989.
17. Proust F, Mannequin D, Langlois O, Freger P, Creissard P: Causes of morbidity and mortality after ruptured aneurysm surgery in a series of 230 patients: The importance of control angiography. Stroke 26:1553-1557, 1995.
18. Säveland H, Brandt L: Which are the major determinants for outcome in aneurysmal subarachnoid hemorrhage? Acta Neurol Scand 90:245-250, 1994.
19. Säveland H, Hillman J, Brandt L, Jakobsson KE, Edner G, Algers G: Causes of morbidity and mortality, with special reference to surgical complications, after early aneurysm operation: A prospective, one year study from neurosurgical units in Sweden. Acta Neurol Scand 88:254-258, 1993.
20. Stachniak JB, Layon J, Day AL, Gallagher J: Craniotomy for intracranial aneurysm, and subarachnoid hemorrhage: Is course, cost, or outcome affected by age? Stroke 27:276-281, 1996.
21. Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC: Costeffectiveness of screening perimenopausal \vhite women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603, 1990.
22. Warner KE, Luce BR: Cost-Benefit and Cost-Effectiveness Analysis in Healtlt Care. Ann Arbor, Health Administration Press, 1982.
23. Weinstein MC, Zeckhauser R: Critical ratios and efficient allocation. J Publ Econ 2:147-157, 1973.
24. Weir BK, Kongable GL, Kassel NF, Schulz JR, Trukowski LL, Sigrest A: Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: A report of the Cooperative Aneurysmal Study. J Ncurosurg 89:405-411, 1998.
25. Wilkins RH: Attempts at prevention or treatment of intracranial arterial spasm: An update. Neurosurgery 18:808-825, 1986.
26. Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. Health Econ 5:297-305, 1996.
27. Williams A: Economics of coronary artery bypass grafting. BMJ 291:326-329, 1985.
28. Yundt KD, Dacey RG Jr, Diringer MN: Hospital resource utilization in the treatment of cerebral aneurysms. J Neurosurg 85:403-409, 1996.